AIRLINK 193.56 Decreased By ▼ -1.27 (-0.65%)
BOP 9.95 Increased By ▲ 0.14 (1.43%)
CNERGY 7.93 Increased By ▲ 0.57 (7.74%)
FCCL 40.65 Increased By ▲ 2.07 (5.37%)
FFL 16.86 Increased By ▲ 0.41 (2.49%)
FLYNG 27.75 Increased By ▲ 0.21 (0.76%)
HUBC 132.58 Increased By ▲ 0.83 (0.63%)
HUMNL 13.89 Increased By ▲ 0.03 (0.22%)
KEL 4.60 Decreased By ▼ -0.06 (-1.29%)
KOSM 6.62 Decreased By ▼ -0.04 (-0.6%)
MLCF 47.60 Increased By ▲ 2.21 (4.87%)
OGDC 213.91 Decreased By ▼ -0.08 (-0.04%)
PACE 6.93 Increased By ▲ 0.07 (1.02%)
PAEL 41.24 Increased By ▲ 1.18 (2.95%)
PIAHCLA 17.15 Increased By ▲ 0.36 (2.14%)
PIBTL 8.41 Increased By ▲ 0.09 (1.08%)
POWER 9.64 Increased By ▲ 0.21 (2.23%)
PPL 182.35 Increased By ▲ 0.16 (0.09%)
PRL 41.96 Increased By ▲ 0.13 (0.31%)
PTC 24.90 Increased By ▲ 0.34 (1.38%)
SEARL 106.84 Increased By ▲ 4.31 (4.2%)
SILK 0.99 Decreased By ▼ -0.01 (-1%)
SSGC 40.10 Increased By ▲ 0.66 (1.67%)
SYM 17.47 Increased By ▲ 0.14 (0.81%)
TELE 8.84 Increased By ▲ 0.08 (0.91%)
TPLP 12.75 No Change ▼ 0.00 (0%)
TRG 66.95 Increased By ▲ 1.55 (2.37%)
WAVESAPP 11.33 Increased By ▲ 0.22 (1.98%)
WTL 1.79 Increased By ▲ 0.09 (5.29%)
YOUW 4.07 Increased By ▲ 0.13 (3.3%)
BR100 12,045 Increased By 70.8 (0.59%)
BR30 36,580 Increased By 433.6 (1.2%)
KSE100 114,038 Increased By 594.4 (0.52%)
KSE30 35,794 Increased By 159 (0.45%)
World Print 2019-11-04

Medicinal cannabis not proven in mental health

Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution, researchers said on Monday.
Published November 4, 2019

Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution, researchers said on Monday.

In a review of scientific studies that analyzed the impact of medicinal cannabinoids on six mental health disorders, the researchers found "a lack of evidence for their effectiveness."

Their findings have important implications for countries such as the United States, Australia, Britain and Canada, where medical cannabis is being made available for patients with certain illness, said Louisa Degenhardt, a drug and alcohol expert at Australia's University of New South Wales in Sydney.

"There is a notable absence of high-quality evidence to properly assess the effectiveness and safety of medicinal cannabinoids and until evidence from randomized controlled trials is available, clinical guidelines cannot be drawn up around their use in mental health disorders," she said as her results were published in The Lancet Psychiatry journal.

Copyright Reuters, 2019

Comments

Comments are closed.